Molecular Docking and Network Pharmacology Interaction Analysis of Gingko Biloba (EGB761) Extract with Dual Target Inhibitory Mechanism in Alzheimer’s Disease
Affiliations: [a] Department of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida, India
| [b] Flinders Health and Medical Research Institute, College of Medicine & Public Health, Flinders University, Adelaide, Australia
| [c] Macquarie Medical School, Macquarie University, Sydney, Australia
| [d] Department of Pharmacognosy, Era College of Pharmacy, Era University, Lucknow, Uttar Pradesh, India
| [e] Department of Pharmacognosy, Amity Institute of Pharmacy, Lucknow, Amity University, UttarPradesh, Noida, India
Correspondence:
[*]
Correspondence to: Manisha Singh, Department of Biotechnology, Jaypee Institute of Information Technology (JIIT), Noida 201309, India. E-mail: manishasingh1295@gmail.com.
Abstract: Background:Alzheimer’s disease (AD) is the most common type of neurodegenerative dementia affecting people in their later years of life. The AD prevalence rate has significantly increased due to a lack of early detection technology and low therapeutic efficacy. Despite recent scientific advances, some aspects of AD pathological targets still require special attention. Certain traditionally consumed phytocompounds have been used for thousands of years to treat such pathologies. The standard extract of Gingko biloba (EGB761) is a combination of 13 macro phyto-compounds and various other micro phytocompounds that have shown greater therapeutic potential against the pathology of AD. Objective:Strong physiological evidence of cognitive health preservation has been observed in elderly people who keep an active lifestyle. According to some theories, consuming certain medicinal extracts helps build cognitive reserve. We outline the research employing EGB761 as a dual target for AD. Methods:This study investigates various inhibitory targets against AD using computational approaches such as molecular docking, network pharmacology, ADMET (full form), and bioactivity prediction of the selected compounds. Results:After interaction studies were done for all the phytoconstituents of EGB761, it was concluded that all four of the phytocompounds (kaempferol, isorhamnetin, quercetin, and ginkgotoxin) showed the maximum inhibitory activity against acetylcholinesterase (AChE) and GSK3β. Conclusion:The highly active phytocompounds of EGB761, especially quercetin, kaempferol, and isorhamnetin, have better activity against AChE and GSK3β than its reported synthetic drug, according to molecular docking and network pharmacology research. These compounds may act on multiple targets in the protein network of AD. The AChE theory was primarily responsible for EGB761’s therapeutic efficacy in treating AD.
